Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
CoreCivic (CXW) - A Defensive Cash Generator the Street Still Undervalues
Contracts, steady cash flow and improving operating leverage create asymmetric upside from ~ $19 stock price; political noise overhangs valuation but fundamentals point to a position-sized long.
CoreCivic is a cash-generative owner/operator of correctional, detention and reentry facilities. Recent quarters show revenue acceleration (Q1-Q3 2025...
Workday (WDAY): Buy on Durable Growth, Cheapening Multiple, and Margin Upside - I Remain Long
Operational momentum + cash-flow conversion support a tactical long with defined entry, stop and two targets.
Workday's enterprise HCM/financial suite is showing sequential revenue and profitability improvement, steady operating cash flow and a clean balance s...
Sandisk (SNDK): Buy the AI-Storage Leader on the Dip — Tactical Position with a Multi-Quarter View
Vertically integrated NAND + SSD repackaging meets insatiable AI capacity demand. Fundamentals are healing; the stock already priced for growth — buy with defined stops.
Sandisk sits at the center of the AI storage wave: vertically integrated NAND production (JV with Kioxia), rapid revenue recovery, and improving cash ...
Buenaventura (BVN): Position for a 2026 Production Inflection - Buy on Weakness or Breakout
A trade idea targeting a material re-rating as operating investments, dividends and equipment wins suggest a 2026 inflection — plan entries, stops and targets.
Buenaventura's stock has already rallied from the low teens to the upper 20s in the past year, but recent operational signals (equipment orders, optio...
Power Integrations: A Growth Name Punted — Trade the Rebound with a Defined Risk
Quality balance sheet, healthy gross margins and steady cash flow — but near-term execution has the stock in the penalty box. Buy the recovery with tight stops.
Power Integrations (POWI) is a cash-generative power-IC specialist with durable margins and a conservative balance sheet that has seen its share price...
Margin Recovery Powers MYR Group - Upgrade to Long (Swing Trade)
Sequential margin improvement and cleaner cash flow create a tactical, risk-managed long opportunity in MYRG
MYR Group's latest quarter shows clear margin recovery: Q3 2025 revenues of $950.4m and diluted EPS of $2.05, with operating income and cash flow tren...
Barclays: Re-rating to 15% ROTE Looks Reasonable - Tactical Long with Defined Stops
Market is finally catching up to improving returns; trade idea: accumulate BCS with tight risk controls.
Barclays (BCS) appears positioned for a re-rating if management can deliver improved return on tangible equity (ROTE) toward 15% as suggested by recen...
Barings BDC: Buy the NAV Discount on a High-Yield, Improving Operating Run-Rate
Trading idea — capture an ~18% NAV discount while collecting a double-digit yield and watching for deleveraging catalysts
Barings BDC (BBDC) is trading meaningfully below book value despite steady earnings, a rising revenue run-rate, and an attractive declared dividend th...
Shake Shack After the Flush - A High-Conviction Long-Term Buy Around $80
Operational recovery, strong cash flow and an approachable valuation make the post-crash pullback a buying opportunity — with a clear risk plan.
Shake Shack (SHAK) recently retraced sharply from 2024 highs; underlying business trends show sequential revenue and profit recovery, positive operati...
Vertex at the Crossroads: Defend the CF Franchise While Funding the Next Wave of High-Margin Growth
A tactical long trade: buy on weakness, use tight risk control — thesis rests on strong cash flow, expanding pipeline, and shareholder-friendly capital allocation.
Vertex remains the dominant cystic fibrosis (CF) franchise owner while building a high-value pipeline in gene editing (Casgevy), pain (Journavx), kidn...
Aldeyra (ALDX) - Binary March 2026 FDA Call Makes a High-Risk, Asymmetric Long Worth a Small Position
Reproxalap approval is the defining event; current price, balance sheet and burn support a time-limited, catalyst-driven trade.
Aldeyra's Reproxalap NDA sits on a March 2026 FDA decision that will determine the company's trajectory. The stock is trading around $5 and the compan...
ADT: Cheap, Cash-Generative, And Misunderstood - A Tactical Long
Under $10, high margins and steady cash flow make ADT a pragmatic buy; trade plan with entry, stop, and two targets.
ADT is a recurring-revenue security and smart-home services business that is generating high operating cash flow, paying a modest dividend, and carryi...